ES2768606T3 - Compuesto de hidrogel de sílice - Google Patents

Compuesto de hidrogel de sílice Download PDF

Info

Publication number
ES2768606T3
ES2768606T3 ES14739213T ES14739213T ES2768606T3 ES 2768606 T3 ES2768606 T3 ES 2768606T3 ES 14739213 T ES14739213 T ES 14739213T ES 14739213 T ES14739213 T ES 14739213T ES 2768606 T3 ES2768606 T3 ES 2768606T3
Authority
ES
Spain
Prior art keywords
silica
weight
microparticles
hydrogel
sol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14739213T
Other languages
English (en)
Spanish (es)
Inventor
Mika Jokinen
Harry Jalonen
Ari-Pekka Forsback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DelSiTech Oy
Original Assignee
DelSiTech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DelSiTech Oy filed Critical DelSiTech Oy
Application granted granted Critical
Publication of ES2768606T3 publication Critical patent/ES2768606T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0073—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Silicon Compounds (AREA)
ES14739213T 2013-06-24 2014-06-18 Compuesto de hidrogel de sílice Active ES2768606T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20135685 2013-06-24
PCT/FI2014/050492 WO2014207304A1 (en) 2013-06-24 2014-06-18 Silica hydrogel composite

Publications (1)

Publication Number Publication Date
ES2768606T3 true ES2768606T3 (es) 2020-06-23

Family

ID=51178958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14739213T Active ES2768606T3 (es) 2013-06-24 2014-06-18 Compuesto de hidrogel de sílice

Country Status (14)

Country Link
US (1) US9949922B2 (cg-RX-API-DMAC7.html)
EP (1) EP3013317B1 (cg-RX-API-DMAC7.html)
JP (1) JP6433490B2 (cg-RX-API-DMAC7.html)
CN (1) CN105451713B (cg-RX-API-DMAC7.html)
AU (1) AU2014300888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2912483C (cg-RX-API-DMAC7.html)
DK (1) DK3013317T3 (cg-RX-API-DMAC7.html)
ES (1) ES2768606T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200134T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047897T2 (cg-RX-API-DMAC7.html)
LT (1) LT3013317T (cg-RX-API-DMAC7.html)
PL (1) PL3013317T3 (cg-RX-API-DMAC7.html)
PT (1) PT3013317T (cg-RX-API-DMAC7.html)
WO (1) WO2014207304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
PL3365020T3 (pl) * 2015-10-22 2020-03-31 Delsitech Oy Preparat depot kompozytu hydrożelowego
FI20155779A7 (fi) 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
WO2018102480A1 (en) * 2016-11-30 2018-06-07 Brown University Methods of fabricating hyper compliant polymer particles and methods of use and compositions
CA3088700A1 (en) * 2018-01-23 2019-08-01 Ascend Biopharmaceuticals Ltd Enhanced viral delivery formulation
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019290582A1 (en) 2018-06-19 2021-01-28 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease
KR20200051916A (ko) * 2018-11-05 2020-05-14 주식회사 메디포럼제약 고세렐린을 포함하는 실리카 하이드로겔 조성물
EP4009857B1 (en) * 2019-08-06 2025-08-20 DOSE Medical Corporation Bioerodible cross-linked hydrogel implants and related methods of use
CN111443012B (zh) * 2020-04-09 2021-07-20 华南理工大学 基于复合波等变率温度扫描流变的聚合物凝胶点表征方法
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
WO2022008804A1 (en) 2020-07-07 2022-01-13 Sartar Therapeutics Ltd Silica hydrogel composite and its use
IL301609A (en) * 2020-10-01 2023-05-01 Standard Millox Pharmaceuticals Oy Hydrogel material
US20240197623A1 (en) * 2021-04-07 2024-06-20 Stealth Bio Therapeutics Inc. Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
KR20250092172A (ko) 2022-09-01 2025-06-23 옵티파이 테라퓨틱스 아게 안과용 조성물
AU2024304630A1 (en) 2023-06-15 2025-12-11 Delsitech Oy Injectable composite depot
WO2026083006A1 (en) 2024-10-18 2026-04-23 Delsitech Oy Silica hydrogel composite comprising an active agent
WO2026125822A1 (en) 2024-12-13 2026-06-18 Delsitech Oy Silica hydrogel composite with a water soluble additive

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332968A (en) * 1996-05-29 2000-08-25 Bioxid Oy A controllably dissolvable silica-xerogel prepared via sol-gel
DE10301669A1 (de) * 2003-01-17 2004-07-29 Gesellschaft zur Förderung von Medizin-, Bio- und Umwelttechnologien e.V. Bioaktive keramische Kompositmaterialien und Verfahren zu deren Herstellung
CA2555179A1 (en) 2004-02-27 2005-09-09 Delsitech Oy Method for preparing adjustably bioresorbable sol-gel derived sio2
GB0420016D0 (en) * 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
WO2007135224A2 (en) 2006-05-23 2007-11-29 Delsitech Oy Method for storing silica-based material, package produced with the method and use of package for packaging of silica-based products
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
US20090324695A1 (en) 2008-05-30 2009-12-31 Paul Ducheyne Biocompatible polymer ceramic composite matrices
KR101068873B1 (ko) 2008-11-28 2011-09-30 연세대학교 산학협력단 바이오마커가 고정된 실리카 나노입자를 함유하는 하이드로젤 및 그 제조방법
US9987225B2 (en) 2009-09-30 2018-06-05 Ottawa Hospital Research Institute Crosslinked hydrogels and related method of preparation

Also Published As

Publication number Publication date
EP3013317A1 (en) 2016-05-04
WO2014207304A1 (en) 2014-12-31
US20160136088A1 (en) 2016-05-19
CN105451713B (zh) 2019-04-23
HUE047897T2 (hu) 2020-05-28
PL3013317T3 (pl) 2020-05-18
US9949922B2 (en) 2018-04-24
JP6433490B2 (ja) 2018-12-05
LT3013317T (lt) 2020-03-10
CA2912483C (en) 2021-06-15
EP3013317B1 (en) 2019-12-04
PT3013317T (pt) 2020-02-19
CA2912483A1 (en) 2014-12-31
HRP20200134T1 (hr) 2020-08-21
AU2014300888B2 (en) 2019-01-17
AU2014300888A1 (en) 2015-12-10
DK3013317T3 (da) 2020-02-17
JP2016522243A (ja) 2016-07-28
CN105451713A (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
US9949922B2 (en) Silica hydrogel composite
Liu et al. Nanoparticle-loaded gels for topical delivery of nitrofurazone: effect of particle size on skin permeation and retention
JP5848326B2 (ja) ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法
US20100119500A1 (en) Method for preparing silica compositions, silica compositions and uses thereof
Alatawi et al. Nanostructured lipid carriers (NLCs) as effective drug delivery systems: methods of preparation and their therapeutic applications
US20240009115A1 (en) Drug delivery systems
CA3201129A1 (en) Material and method for treating cancer
CN115227639A (zh) 一种温敏改性甲壳素水凝胶载局部麻药缓释镇痛体系、制备方法及应用
Xiong et al. A silk-based hydrogel containing dexamethasone and lipoic acid microcrystals for local delivery to the inner ear
ES2947659T3 (es) Método de procesamiento para biopolímeros usando combinaciones de solventes
US12377149B2 (en) Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3D printing bioink
CN101822636A (zh) 可注射雌三醇缓控释给药系统
EP4319786A1 (en) Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
CN105199115A (zh) 一种多孔渗水的三维网状结构的可注射水凝胶的制备及其应用
US20230248647A1 (en) Silica hydrogel composite and its use
WO2026083006A1 (en) Silica hydrogel composite comprising an active agent
Shete et al. Microspheres as a Unique Drug Carrier for Controlled Drug Delivery: A Review
BR112021013136B1 (pt) Método para a produção de uma carga que contém uma microcápsula dupla de ácido poli-l-láctico e ácido hialurônico
WO2026081528A1 (zh) 利用小粒径药物微粒制备缓释微球的方法及制备的微球
EP4727587A1 (en) Injectable composite depot
Liu et al. Sustained-Release Nintedanib-Loaded Microspheres for the Treatment of Idiopathic Pulmonary Fibrosis
Wang et al. Prolongation of Local Anesthesia Through a Dual System of Dopamine Nanoparticles and a Thermosensitive Hydrogel